ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Annual Report Finds Decreases In Overall Cancer Rates

December 11, 2009

In Brief: Nearly One-Third Of Cancer Radiotherapy Facilities Use Outdated Methods – Clark

August 9, 1974

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

Holland, Leader Win $250,00 Milken Awards: Six Others Get $50,000 Prizes

December 9, 1988

Komen Foundation Offer Fellowships

February 9, 1996

New Core Gant Guideline Proposals Drawn Up; Opposition Developing Among Center Directors

April 4, 1980